Optimising glycaemic control — the role of long-acting insulin analogues in basal insulin therapy

Abstract

Current insulin treatment regimens effectively combat post-prandial hyperglycaemia, but are unable to reinstate normal fasting plasma glucose concentrations. The advent of long-acting soluble insulin analogues, such as insulin glargine and insulin detemir, offers improved control of basal hyperglycaemia without increasing the risk of hypoglycaemia.

Keywords

glycaemic control insulin treatment basal insulin insulin analogues insulin glargine insulin detemir.

Get full access to this article

View all access options for this article.

References

Owens DR , Zinman B. , Bolli GB Insulins today and beyond. Lancet 2001; 358:739-46.

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999;48:383-90.

Lepore M. , Pampanelli S. , Fanelli CG et al. Pharmacokinetics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, ultralente human insulin, and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8.

Heinemann L. , Weyer C. , Rauhaus M. , Heinrichs S. , Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998;21:1910-14.

Rosskamp RH , Park G. Long-acting insulin analogs. Diabetes Care 1999; 22(suppl 2):B109-13.

Koivisto VA The human insulin analogue insulin lispro. Ann Med 1998; 30:260-6.

Simpson KL , Spencer CM Insulin aspart. Drugs 1999;57:759-65.

10.

Bolli GB , Owens DR Insulin glargine. Lancet 2000;356:443-5.

11.

McKeague K. , Goa KL Insulin glargine. A review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus . Drugs 2001;61:1599-624.

12.

Pieber TP , Eugene-Jolcine I. , Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000; 23:157-62.

13.

Rosenstock J. , Park G. , Zimmerman J. Basal Insulin Glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000;23:1137-42.

14.

Hershon K. , Blevins T. , Donley D. , Littlejohn C. Lower fasting blood glucose (FBG) and less symptomatic hypoglycemia with QD insulin glargine (Lantus) compared to BID NPH in subjects with type 1 diabetes [abstract]. Diabetes 2001;50(suppl 2):116-17.

15.

Ratner RE , Hirsch IB , Neifing JL , Garg SK , Mecca TE , Wilson CA Less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000;23:639-43.

16.

Standl E. Results of an international, multicentred, randomised, 28 week study for the comparison of glargine insulin (HOE 901) and NPH insulin in the intensified treatment (ICT) of type 1 diabetics [abstract]. Exp Clin Endocrinol Diabetes 2000;108(suppl 1):159.

17.

Raskin P. , Klaff L. , Bergenstal R. , Halle JP , Donley D. , Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes . Diabetes Care 2000;23:1666-71.

18.

Schoenle E. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycaemia [abstract]. Diabetologia 1999;42(suppl 1):A235.

19.

Matthews DR , Pfeiffer C. Comparative clinical trial of a new long-acting insulin (HOE 901) vs protamine insulin demonstrates less nocturnal hypoglycaemia. Multicentre HOE 901 Research Group [abstract]. Diabetes 1998;47(suppl 1):A101.

20.

Raskin P. , Park G. , Zimmerman J. The effect of HOE 901 on glycaemic control in type 2 diabetes [abstract]. Diabetes 1998;47(suppl 1):A103.

21.

Rosenstock J. , Schwartz SL , Clark CM Jr , Park GD , Donley DW , Edwards MB Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6.

22.

Fonseca V. , Bell D. , Mecca T. Less symptomatic hypoglycaemia with bedtime insulin glargine (Lantus) compared to bedtime NPH insulin in patients with type 2 diabetes [abstract]. Diabetes 2001;50(suppl 2):112-13.

23.

Massi Benedetti M. Results of a 12-month study: insulin glargine (HOE 901) in combination with oral agents [abstract]. 35th Annual Meeting of the European Association for the Study of Diabetes (EASD); Brussels, 9-13 September 1999 .

24.

Yki-Jarvinen H. , Dressler A. , Ziemen M. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6.

25.

Rosenstock J. , Riddle M. , Dailey G. , Gerich J. , Mecca T. , Wilson C. , Bugos C. Treatment to target study: feasibility of achieving control with the addition of basal bedtime insulin glargine (Lantus®) or NPH in insulin-naïve patients with type 2 diabetes on oral agents [poster] . American Diabetes Association, 61st Scientific Sessions, Philadelphia, USA, 22-26 June 2001.

26.

Witthaus E. , Stewart J. , Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabetic Med 2001;8:619-25.

27.

Witthaus E. , Stewart J. , Bradley C. Improved psychological outcomes after initiation of insulin treatment in patients with type II diabetes. Abstract. Diabetologia 2000;43(suppl 1):A205.